Fenoterol hydrobromide 非诺特罗氢溴酸盐; Th-1165a; Phenoterol hydrobromide|cas:1944-12-3|西域试剂

Fenoterol hydrobromide 非诺特罗氢溴酸盐; Th-1165a; Phenoterol hydrobromide,99.90%

产品编号：Bellancom-B0976A| CAS NO：1944-12-3| 分子式：C₁₇H₂₂BrNO₄| 分子量：384.26

Fenoterol溴酸盐是一个β 2肾上腺素能激动剂, 用于打通呼吸道到肺部, 被归类为交感神经β2激动剂和哮喘药物。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-B0976A		￥700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Fenoterol hydrobromide 非诺特罗氢溴酸盐; Th-1165a; Phenoterol hydrobromide

产品介绍

Fenoterol hydrobromide (Th-1165a) 是拟交感神经剂，是一种选择性的，具有口服活性 β2-肾上腺素受体 (β2-adrenoceptor) 激动剂。Fenoterol hydrobromide 是一种有效的支气管扩张剂，可用于与哮喘，支气管炎和其他阻塞性气道疾病相关的支气管痉挛的研究。

生物活性

Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol hydrobromide is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.

体外研究

Fenoterol (1 μM; pre-incubated 30 minutes) treatment reduces AICAR-induced AMPK activation, NF-κB activation and TNF-α release, and also significantly downregulates the elevated phosphorylation levels of AMPK.
Fenoterol inhibits lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells.
Fenoterol is also a potent exosome biogenesis and/or secretion activator in PC cells^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	THP-1 cells stimulated with AICAR
Concentration:	1 μM
Incubation Time:	Pre-incubated 30 minutes
Result:	Significantly downregulated the elevated phosphorylation levels of AMPK.

体内研究
(In Vivo)

Fenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice (6 weeks old) with neuropathy
Dosage:	0.7 mg/kg
Administration:	Intraperitoneal injection; twice a day; for 3 weeks
Result:	Alleviated neuropathic allodynia during chronic treatment.

体内研究

Fenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice (6 weeks old) with neuropathy
Dosage:	0.7 mg/kg
Administration:	Intraperitoneal injection; twice a day; for 3 weeks
Result:	Alleviated neuropathic allodynia during chronic treatment.

体内研究

Fenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice (6 weeks old) with neuropathy
Dosage:	0.7 mg/kg
Administration:	Intraperitoneal injection; twice a day; for 3 weeks
Result:	Alleviated neuropathic allodynia during chronic treatment.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (260.24 mM)

H₂O : 25 mg/mL (65.06 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6024 mL	13.0120 mL	26.0240 mL
5 mM	0.5205 mL	2.6024 mL	5.2048 mL
10 mM	0.2602 mL	1.3012 mL	2.6024 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 60 mg/mL (156.14 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.51 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.51 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.51 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

. R C Heel, et al. Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs. 1978 Jan;15(1):3-32. [Content Brief]

. Wei Wang, et al. Anti-inflammatory activities of fenoterol through β-arrestin-2 and inhibition of AMPK and NF-κB activation in AICAR-induced THP-1 cells. Biomed Pharmacother. 2016 Dec;84:185-190. [Content Brief]

. Nada Choucair-Jaafar, et al. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br J Pharmacol. 2009 Dec;158(7):1683-94. [Content Brief]

[4]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS07
信号词	Warning
危害声明	H302
警示性声明	P301 + P312 + P330
个人防护装备	dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲)	Xn
风险声明 (欧洲)	22
安全声明 (欧洲)	36
危险品运输编码	UN 3249
WGK德国	3
RTECS号	DO1500000
包装等级	III
海关编码	29225090

Fenoterol hydrobromide 非诺特罗氢溴酸盐; Th-1165a; Phenoterol hydrobromide,99.90%

Fenoterol hydrobromide 非诺特罗氢溴酸盐; Th-1165a; Phenoterol hydrobromide

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询